Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Panelists discusses how the ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...

Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help prevent further damage to ...

ERS issues new bronchiectasis guidelines to improve patient care, standardise treatment, and reduce variability in global ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

Please provide your email address to receive an email when new articles are posted on . Adults with a long-term smoking history suspected to have bronchiectasis faced an elevated mortality risk ...

Please provide your email address to receive an email when new articles are posted on . The FDA based brensocatib’s approval on phase 3 ASPEN and phase 2 WILLOW trial results. This marks the first ...

Most often secondary to childhood infection, bronchiectasis is irreversible. But there are steps you can take to improve your patients’ quality of life. Bronchiectasis, which is characterized by ...

Coughing up blood, or haemoptysis, can indicate serious underlying conditions like tuberculosis, bronchiectasis, or even lung cancer. Studies reveal that untreated massive haemoptysis carries a high ...